メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
平田 賢郎
医学部腫瘍センター
ウェブサイト
https://k-ris.keio.ac.jp/html/100003002_ja.html
h-index
1486
被引用数
22
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2006
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(56)
類似のプロファイル
(6)
フィンガープリント
Kenro Hirataが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Helicobacter Pylori
100%
Chemotherapy
58%
Stomach Cancer
55%
Overall Survival
46%
Rifabutin
42%
Malignant Neoplasm
38%
Amoxicillin
32%
Ramucirumab
28%
Phase II Trials
28%
Pancreas Cancer
28%
Progression Free Survival
25%
Clarithromycin
19%
Adenocarcinoma
17%
Fluorouracil
17%
Clinical Trial
16%
Reactive Oxygen Metabolite
16%
Gemcitabine
15%
Minimal Residual Disease
14%
Metastatic Colorectal Cancer
14%
Oral Mucositis
14%
Recurrent Disease
14%
Observational Study
14%
Chromatin Immunoprecipitation
14%
Gallstone
14%
Overactive Bladder
14%
Dyspepsia
14%
Vasculotropin
14%
Paclitaxel
14%
Clinical Research
14%
Esophageal Squamous Cell Carcinoma
14%
Second-Line Chemotherapy
14%
Pyogenic Granuloma
14%
Nivolumab
14%
Effusion
14%
Immune Checkpoint Inhibitor
14%
Ferric Uptake Regulator
14%
microRNA
14%
CD44v Antigen
14%
Ipilimumab
14%
First-Line Chemotherapy
14%
CagA
14%
Trifluridine
14%
Tipiracil
14%
Sitafloxacin
14%
Tipiracil Plus Trifluridine
14%
Adverse Event
13%
Enterocolitis
10%
Gastroesophageal Reflux
9%
Minimum Inhibitory Concentration
8%
Irritable Colon
8%
Medicine and Dentistry
Esophageal Squamous Cell Carcinoma
42%
Stomach Cancer
31%
Pyogenic Granuloma
28%
Ramucirumab
28%
Immune Checkpoint Inhibitor
28%
Phase II Trials
28%
Barrett Esophagus
28%
Metaplasia
28%
Odds Ratio
27%
Gastroesophageal Reflux
25%
Overall Survival
25%
Malignant Neoplasm
25%
Adenocarcinoma
22%
Neoadjuvant Chemotherapy
22%
Chemoradiotherapy
21%
Gallstone
20%
Quality of Life
20%
Dyspepsia
19%
Colorectal Cancer
18%
Capsule Endoscopy
17%
Neoplasm
17%
Small Intestine
17%
Oncology
16%
Retrospective Study
16%
Hazard Ratio
15%
Nivolumab
15%
Clinical Trial
14%
Arm
14%
Minimal Residual Disease
14%
Symptom
14%
Rescue Therapy
14%
Sitafloxacin
14%
Observational Study
14%
Ipilimumab
14%
Overactive Bladder
14%
Fat Content
14%
Esophagus
14%
microRNA 155
14%
Prevalence
14%
Oral Mucositis
14%
Rectum Cancer
14%
Low Drug Dose
14%
Intraductal Papillary Mucinous Tumor
14%
Paclitaxel
14%
Pneumonia
14%
Solid Malignant Neoplasm
14%
Vasculotropin
14%
Metastatic Colorectal Cancer
14%
Esophageal Varices
14%
Helicobacter Pylori
14%
Keyphrases
Pyogenic Granuloma
28%
CD44 Variant 9
28%
Chemoradiotherapy
25%
Neoadjuvant Chemotherapy
22%
Obscure Gastrointestinal Bleeding
17%
Capsule Endoscopy
17%
Triple Therapy
17%
Later-line
17%
Small Intestine
17%
Hazard Ratio
16%
Overall Survival
16%
Esophageal Squamous Cell Carcinoma
16%
Second-line Therapy
15%
Residual Disease
14%
Imaging Progression
14%
Time Management
14%
Muscle-specific microRNAs
14%
Gastric Cancer
14%
Esophageal Metaplasia
14%
Multicenter Retrospective Study
14%
Reflux Symptoms
14%
Functional Dyspepsia
14%
GerdQ
14%
Overactive Bladder Symptom Score (OABSS)
14%
GerdQ Questionnaire
14%
Eradication Therapy
14%
Rifabutin
14%
Immune Checkpoint Inhibitors
14%
7-day Triple Therapy
14%
Helicobacter Pylori Eradication
14%
MiR-142-5p
14%
Adenocarcinoma of the Esophagogastric Junction
14%
Post-progression Survival
14%
RNA Interference
14%
Immune-mediated Colitis
14%
MicroRNA-29c
14%
MiR-29a
14%
Recurrence Pattern
14%
Anti-VEGF Therapy
14%
FOLFOXIRI
14%
Prospective Observational Study
14%
Older Patients
14%
Real-world Outcomes
14%
Ferric Uptake Regulator
14%
5-fluorouracil Resistance
14%
Esophageal Varices
14%
Columnar-lined Esophagus
14%
Randomized Phase II Trial
14%
Iron Transporter
14%
Clinical Characteristics
14%
